JP2016509030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509030A5 JP2016509030A5 JP2015558225A JP2015558225A JP2016509030A5 JP 2016509030 A5 JP2016509030 A5 JP 2016509030A5 JP 2015558225 A JP2015558225 A JP 2015558225A JP 2015558225 A JP2015558225 A JP 2015558225A JP 2016509030 A5 JP2016509030 A5 JP 2016509030A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet
- pain
- capsule
- neuropathic pain
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 17
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 14
- 208000004296 neuralgia Diseases 0.000 claims description 14
- 208000021722 neuropathic pain Diseases 0.000 claims description 12
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- -1 opioid Substances 0.000 claims description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000000561 anti-psychotic effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 201000005518 mononeuropathy Diseases 0.000 claims description 2
- 239000004050 mood stabilizer Substances 0.000 claims description 2
- 229940127237 mood stabilizer Drugs 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 230000001953 sensory effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 7
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000024825 childhood disintegrative disease Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767017P | 2013-02-20 | 2013-02-20 | |
| US61/767,017 | 2013-02-20 | ||
| PCT/US2014/017432 WO2014130691A2 (en) | 2013-02-20 | 2014-02-20 | Pharmaceutical formulations of nitrite and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016509030A JP2016509030A (ja) | 2016-03-24 |
| JP2016509030A5 true JP2016509030A5 (enExample) | 2017-02-02 |
Family
ID=51391970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558225A Pending JP2016509030A (ja) | 2013-02-20 | 2014-02-20 | ニトライトの医薬製剤及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9561249B2 (enExample) |
| EP (1) | EP2958573B1 (enExample) |
| JP (1) | JP2016509030A (enExample) |
| KR (1) | KR102472588B1 (enExample) |
| CN (1) | CN105358160A (enExample) |
| AU (1) | AU2014218916A1 (enExample) |
| BR (1) | BR112015019802A2 (enExample) |
| CA (1) | CA2899602C (enExample) |
| DK (1) | DK2958573T3 (enExample) |
| ES (1) | ES2741146T3 (enExample) |
| HK (1) | HK1218079A1 (enExample) |
| WO (1) | WO2014130691A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9649334B2 (en) * | 2007-11-15 | 2017-05-16 | The Uab Research Foundation | Use of nitrite salts in chronic ischemia |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
| GB201602959D0 (en) | 2016-02-19 | 2016-04-06 | Isis Innovation | Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury |
| CA3026639A1 (en) * | 2016-06-06 | 2017-12-14 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Uses of inorganic nitrite for increasing nerve conduction velocity |
| US12023173B2 (en) * | 2017-07-14 | 2024-07-02 | Pamela, Inc. | Pain classification and momentary-pain determination using sparse modeling |
| CN108785106B (zh) * | 2018-06-05 | 2021-03-16 | 中国科学院上海硅酸盐研究所 | 一种胶状含银磷酸钙纳米复合材料及其制备方法和应用 |
| WO2020141546A1 (en) | 2019-01-02 | 2020-07-09 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for pain management |
| TW202116300A (zh) * | 2019-10-28 | 2021-05-01 | 美商阿卡蒂亞藥品公司 | 用於治療雷特氏症候群的方法與組成物 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4650484A (en) | 1983-02-03 | 1987-03-17 | Alza Corporation | Method for treating ischemic conditions |
| IE64726B1 (en) | 1987-11-20 | 1995-08-23 | Elan Corp Plc | Pharmaceutical formulations for preventing drug tolerance |
| US5122384A (en) | 1989-05-05 | 1992-06-16 | Kv Pharmaceutical Company | Oral once-per-day organic nitrate formulation which does not induce tolerance |
| US5278192A (en) | 1992-07-02 | 1994-01-11 | The Research Foundation Of State University Of New York | Method of vasodilator therapy for treating a patient with a condition |
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| US20110196039A9 (en) | 1994-10-05 | 2011-08-11 | Kaesemeyer Wayne H | Controlled release arginine formulations |
| US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
| US5692500A (en) * | 1995-01-09 | 1997-12-02 | Gaston-Johansson; Fannie | Pain measurement and recording tool and method |
| US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
| US7371415B1 (en) | 1998-04-03 | 2008-05-13 | The Daily Wellness Company | Method and composition for improving sexual fitness |
| US7015876B1 (en) | 1998-06-03 | 2006-03-21 | Lear Corporation | Heads-up display with improved contrast |
| EP1105146A1 (en) | 1998-07-14 | 2001-06-13 | Paracelsian, Inc. | Method for identifying and confirming consistent bio-functionality of natural compositions |
| NZ513037A (en) | 1999-01-29 | 2003-05-30 | Disphar Internat B | Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract |
| GB9905425D0 (en) | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
| GB0119011D0 (en) | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| JP2005524676A (ja) * | 2002-03-20 | 2005-08-18 | ザ・ユニバーシティ・オブ・クイーンズランド | 一酸化窒素供与体及びオピオイド鎮痛薬を含む方法及び組成物 |
| CA2379211A1 (fr) | 2002-03-28 | 2003-09-28 | Institut De Cardiologie De Montreal | Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase) |
| CA2537222A1 (en) | 2003-07-09 | 2005-01-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
| WO2005018561A2 (en) | 2003-08-20 | 2005-03-03 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
| WO2005023189A2 (en) | 2003-09-03 | 2005-03-17 | Pharmacia Corporation | Method of cox-2 selective inhibitor and nitric oxide-donating agent |
| US7362274B1 (en) | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
| US20060083824A1 (en) | 2004-10-20 | 2006-04-20 | Pbm Products Llc | Nutritional supplements for glucose intolerant individuals |
| WO2006128032A2 (en) | 2005-05-24 | 2006-11-30 | Wellgen, Inc. | Compositions and methods for the prevention and treatment of conditions associated with inflammation |
| GB0607402D0 (en) | 2006-04-12 | 2006-05-24 | Barts & London Nhs Trust | Therapeutic composition and use |
| US8333997B2 (en) | 2006-06-21 | 2012-12-18 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof |
| HUE031982T2 (en) | 2007-02-26 | 2017-08-28 | Heartbeet Ltd | Performance enhancing composition and use thereof |
| JP2010519336A (ja) | 2007-02-26 | 2010-06-03 | ルンドベルク，ヨン | 亜硝酸塩及び硝酸塩及びこれらを含む組成物の新規使用 |
| WO2008153762A2 (en) | 2007-05-25 | 2008-12-18 | N30 Pharmaceuticals, Llc | S-nitrosothiol formulations and storage systems |
| US9649334B2 (en) | 2007-11-15 | 2017-05-16 | The Uab Research Foundation | Use of nitrite salts in chronic ischemia |
| EP2237788A4 (en) | 2007-12-27 | 2013-06-05 | Aires Pharmaceuticals Inc | COMPOUNDS FOR OBTAINING AEROSOLIZED NITRITE AND NITRIC OXIDE AND USES THEREOF |
| WO2010036236A1 (en) | 2008-09-23 | 2010-04-01 | Baker Hughes Incorporated | Anchor assembly |
| US8568793B2 (en) | 2009-02-11 | 2013-10-29 | Hope Medical Enterprises, Inc. | Sodium nitrite-containing pharmaceutical compositions |
| US20120237617A1 (en) * | 2009-06-18 | 2012-09-20 | Theravasc Inc. | Use of nitrite salts in treating tissue damage |
| US10463689B2 (en) | 2009-10-14 | 2019-11-05 | Board Of Supervisors Of Louisiana State University | Pharmaceutical formulations of nitrite and uses thereof |
| US20130209584A1 (en) | 2009-10-14 | 2013-08-15 | Theravasc Inc. | Pharmaceutical formulations of nitrite and uses thereof |
| EP2533773B1 (en) * | 2010-10-21 | 2015-08-19 | Kipax Ab | Topical dermal delivery device for nitric oxide delivery |
| WO2012135623A1 (en) | 2011-03-31 | 2012-10-04 | Theravasc Inc. | Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline |
| US20140112983A1 (en) | 2011-04-14 | 2014-04-24 | Theravasc Inc. | Nitrite compositions and uses thereof |
| CN105358160A (zh) * | 2013-02-20 | 2016-02-24 | 瑟阿瓦斯克公司 | 亚硝酸盐的药物制剂及其用途 |
-
2014
- 2014-02-20 CN CN201480022166.1A patent/CN105358160A/zh active Pending
- 2014-02-20 KR KR1020157025763A patent/KR102472588B1/ko active Active
- 2014-02-20 HK HK16106249.8A patent/HK1218079A1/zh unknown
- 2014-02-20 BR BR112015019802A patent/BR112015019802A2/pt not_active IP Right Cessation
- 2014-02-20 JP JP2015558225A patent/JP2016509030A/ja active Pending
- 2014-02-20 ES ES14754330T patent/ES2741146T3/es active Active
- 2014-02-20 WO PCT/US2014/017432 patent/WO2014130691A2/en not_active Ceased
- 2014-02-20 DK DK14754330.0T patent/DK2958573T3/da active
- 2014-02-20 CA CA2899602A patent/CA2899602C/en active Active
- 2014-02-20 AU AU2014218916A patent/AU2014218916A1/en not_active Abandoned
- 2014-02-20 EP EP14754330.0A patent/EP2958573B1/en active Active
-
2015
- 2015-02-19 US US14/626,571 patent/US9561249B2/en active Active
-
2017
- 2017-01-05 US US15/399,208 patent/US20170143759A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509030A5 (enExample) | ||
| Stahl | Mechanism of action of ketamine | |
| JP2012193216A5 (enExample) | ||
| JP2015519329A5 (enExample) | ||
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| JP2013526544A5 (enExample) | ||
| JP2012180381A5 (enExample) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20171739T1 (hr) | Postupci i kompozicije za liječenje simptoma povezanih s posttraumatskim stresnim poremećajem korištenjem ciklobenzaprina | |
| RU2012154447A (ru) | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| IL292465B2 (en) | Neuroactive compounds and methods of use thereof | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| Szabó et al. | Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach | |
| CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
| ME02946B (me) | Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja | |
| JP2013518914A5 (enExample) | ||
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2019526571A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2015522630A5 (enExample) | ||
| JP2016512817A5 (enExample) |